Pulsed‐field versus cryoballoon ablation for atrial fibrillation—Impact of energy source on sedation and analgesia requirement
Journal of Cardiovascular Electrophysiology · 2024-01 · 35 (1) · 162-170
DOI: 10.1111/jce.16141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 27.11.2023. Verfasst von Rahin Wahedi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Intensive Care Medicine, Asklepios Hospital St. Georg, Hamburg, Germany. Hauptthemen laut MEDLINE: Atrial Fibrillation, Propofol, Cryosurgery, Analgesia. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Pulsed field ablation (PFA) represents a novel, nonthermal energy modality that can be applied for single‐shot pulmonary vein isolation (PVI) in atrial fibrillation (AF). Comparative data with regard to deep sedation to established single‐shot modalities such as cryoballoon (CB) ablation are scarce. The aim of this study was to compare a deep sedation protocol in patients receiving PVI with either PFA or CB.
Methods
Prospective, consecutive AF patients undergoing PVI with a pentaspline PFA catheter were compared to a retrospective CB‐PVI cohort of the same timeframe. Study endpoints were the requirements of analgesics, cardiorespiratory stability, and sedation‐associated complications.
Results
A total of 100 PVI patients were included (PFA n = 50, CB n = 50, mean age 66 ± 10.6, 61% male patients, 65% paroxysmal AF). Requirement of propofol, midazolam, and sufentanyl was significantly higher in the PFA group compared to CB [propofol 0.14 ± 0.04 mg/kg/min in PFA vs. 0.11 ± 0.04 mg/kg/min in CB ( p = .001); midazolam 0.00086 ± 0.0004 mg/kg/min in PFA vs. 0.0006295 ± 0.0003 mg/kg/min in CB ( p = .002) and sufentanyl 0.0013 ± 0.0007 µg/kg/min in PFA vs. 0.0008 ± 0.0004 µg/kg/min in CB ( p < .0001)]. Sedation‐associated complications did not differ between both groups (PFA n = 1/50 mild aspiration pneumonia, CB n = 0/50, p > .99). Nonsedation‐associated complications (PFA: n = 2/50, 4%, CB: n = 1/50, 2%, p > .99) and procedure times (PFA 75 ± 31, CB 84 ± 32 min, p = .18) did not differ between groups.
Conclusions
PFA is associated with higher sedation and especially analgesia requirements. However, the safety of deep sedation does not differ to CB ablation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Intensive Care Medicine, Asklepios Hospital St. Georg, Hamburg, Germany.
- Semmelweis University, Budapest, Hungary.
- DZHK (German Center for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Berlin, Germany.
- Asklepios Proresearch, Hamburg, Germany.
ORCID-Profile: Omar Anwar, Nele Gessler, Melanie A Gunawardene
Zitieren
APA
Wahedi, R., Willems, S., Feldhege, J., Jularic, M., Hartmann, J., Anwar, O., Dickow, J., Harloff, T., Gessler, N., & Gunawardene, M. A. (2024). Pulsed‐field versus cryoballoon ablation for atrial fibrillation—Impact of energy source on sedation and analgesia requirement. Journal of Cardiovascular Electrophysiology, 35(1), 162-170. https://doi.org/10.1111/jce.16141
Vancouver
Wahedi R, Willems S, Feldhege J, Jularic M, Hartmann J, Anwar O, et al. Pulsed‐field versus cryoballoon ablation for atrial fibrillation—Impact of energy source on sedation and analgesia requirement. Journal of Cardiovascular Electrophysiology. 2024;35(1):162-170. doi:10.1111/jce.16141
BibTeX
@article{Wahedi2024,
author = {Wahedi, Rahin and Willems, Stephan and Feldhege, Johannes and Jularic, Mario and Hartmann, Jens and Anwar, Omar and Dickow, Jannis and Harloff, Tim and Gessler, Nele and Gunawardene, Melanie A},
title = {Pulsed‐field versus cryoballoon ablation for atrial fibrillation—Impact of energy source on sedation and analgesia requirement},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2024},
volume = {35},
number = {1},
pages = {162--170},
doi = {10.1111/jce.16141}
}
EUVIMED